Pacira BioSciences (PCRX) Cash from Operations (2010 - 2026)

Pacira BioSciences' Cash from Operations history runs 17 years deep, the most recent figure standing at 25680000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 27.58% year-over-year to 25680000.0 in Q1 2026; TTM through Mar 2026 was 142215000.0, a 19.08% decrease from a year earlier, with the FY2025 full-year figure at 151994000.0, down 19.75% from the prior year.
• Cash from Operations fell to 25680000.0 in Q1 2026 per PCRX's latest filing, from 43689000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 60834000.0 in Q3 2025 and bottomed at 12012000.0 in Q2 2025.
• The 5-year median for Cash from Operations is 42654000.0 (2022), against an average of 39234470.59.
• Across the five-year window, Cash from Operations soared 156.7% in 2024 and slumped 77.44% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 42037000.0 in 2022, then increased by 13.2% to 47584000.0 in 2023, then sank by 30.37% to 33132000.0 in 2024, then surged by 31.86% to 43689000.0 in 2025, then tumbled by 41.22% to 25680000.0 in 2026.
• Per Business Quant, the three latest PCRX Cash from Operations figures stand at 25680000.0 (Q1 2026), 43689000.0 (Q4 2025), and 60834000.0 (Q3 2025).